Emapalumab, an IFN-γ-blocking antibody, was successfully tested in a phase 2–3 study in children with primary HLH and is now available as specific cytokine-directed therapy for future therapeutic approaches in patients with primary HLH (18, 52). This evidence concerns the gene IFNG and hemophagocytic syndrome.